T1D Fund
VC / Fund of funds · Boston · United States
Etapas
Región de inversión
Industrias
Perfil
T1D Fund is a venture fund dedicated to catalyzing the development of therapies for Type 1 Diabetes (T1D). Based in Boston, the fund was launched in 2016 as a wholly owned subsidiary of Breakthrough T1D. The team consists of experienced professionals from venture capital, investment banking, pharma, and company building sectors. Their unique approach is focused on accelerating treatments and eventual cures for T1D through strategic investments and partnerships with biopharmaceutical companies and venture capital firms. The fund primarily invests in early-stage biotech companies working on disease-modifying therapies and potential cures for T1D. With over $250 million in assets under management, they reinvest all returns back into new investments, maintaining a cycle aimed at fueling foundational research and therapeutic development. T1D Fund's unique positioning allows it to de-risk investments and attract further interest in the T1D space. Notable companies in their portfolio include Zag Bio, which focuses on thymus-targeted medicines for autoimmune diseases, and Zucara Therapeutics, working on diabetes life sciences. By leveraging its vast clinical, regulatory, and medical network, T1D Fund strives to rapidly advance the development of these promising therapies.
Contactos (2)
| Nombre | Cargo | Teléfono | ||
|---|---|---|---|---|
| Principal | — | — | — | |
| Managing Director | — | — | — |
El nombre, email y teléfono se muestran en sombra. Suscribite para verlos completos.